logo
Plus   Neg
Share
Email

Beckman Coulter Gets FDA Clearance Of New Access AccuTnI+3 Troponin I Assay

Beckman Coulter, Inc., a subsidiary of Danaher Corp. (DHR) Wednesday said the U.S. Food and Drug Administration, or FDA, has granted clearance of its new Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system.

"Clinicians have depended on Beckman Coulter's troponin I test for over 12 years and the new AccuTnI+3 assay has the proven performance to continue providing dependability to laboratories supporting emergency care," said Arnd Kaldowski, president, Beckman Coulter Diagnostics.

In October 2010, the FDA issued guidance to all manufacturers of troponin assays in an effort to modernize the performance evaluation and regulatory review of these critical tests.

In accordance with the FDA's new requirements, Beckman Coulter conducted a large multicenter prospective clinical trial that enrolled over 1,900 subjects. The data from the trial showed that the assay delivers the precision, clinical sensitivity and clinical specificity necessary to assist physicians with the diagnosis of MI.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Netflix Inc. (NFLX) - Shares of the video streaming giant jumped 12% after it reported fourth-quarter results and strong subscriber additions. Netflix added 8.51 million subscribers globally in the quarter, far ahead of its forecast of 6.00 million, to end the quarter with 203.66 million subscribers.... Best Buy said it is partnering Popsockets to bring products designed by teens from the company's community programs to its store shelves. The electronics retailer will sell the teen-designed PopGrips in its stores as part of its "Black History Month" campaign. The campaign is intended to celebrate and encourage young artists. Goldman Sachs Group Inc. (GS) on Tuesday reported a fourth-quarter profit that more than doubled from last year, reflecting a surge in investment banking revenues and lower provisions for bad loans. Net revenues for the quarter rose 18 percent. Both quarterly earnings per share and revenues topped analysts' expectations.
Follow RTT